Inflammatory Bowel Disease (IBD) Therapeutics Market Analysis: Global Industry Size, Growth and Forecast
Report ID : 1330125 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Inflammatory Bowel Disease (IBD) Therapeutics Market is categorized based on Drug Class (Biologics, Immunomodulators, Corticosteroids, Antibiotics, 5-Aminosalicylic Acid (5-ASA)) and Route of Administration (Oral, Injectable, Topical) and End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
Valued at $18.5 billion in 2023, the Inflammatory Bowel Disease (IBD) Therapeutics Market size is expected to grow to $36.2 billion by 2033, with a CAGR of 7.0% from 2024 to 2033. The report comprises various segments and analyzes the trends and factors playing a substantial role in the market.
The global health issue of Inflammatory Bowel Disease (IBD) which includes ulcerative colitis and Crohn's disease has impacted millions of people. Patients suffering from chronic gastrointestinal disorders need therapies that manage symptoms, induce remission, and ultimately improve the patients' quality of life. With growing understanding of the complexities surrounding IBD, its therapeutics market is transforming with great pace, Novel treatment approaches and biologic therapies are continuously being incorporated, which is helping fuel the market.
The therapeutics market for IBD is currently lacks business drivers. In developing regions, the availability of information and education is helping increase the rate of IBD and the level of awareness among healthcare workers. confronting the growing burden of IBD, emerging pharmaceutical markets is inducing competition and investments. A targeted approach is being observed where therapies and medicine is steered towards specific groups or individuals. When analyzing the intricacies of IBD therapeutics, there is a hope that the shift in focus will allow for revolutionary changes in the treatment of this complex condition.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | AbbVie, Johnson & Johnson, Takeda Pharmaceutical Company, Bristol-Myers Squibb, Amgen, Merck & Co., Roche, Novartis, Pfizer, Gilead Sciences, Eli Lilly and Company |
| SEGMENTS COVERED |
By Drug Class - Biologics, Immunomodulators, Corticosteroids, Antibiotics, 5-Aminosalicylic Acid (5-ASA)
By Route of Administration - Oral, Injectable, Topical
By End User - Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Inflammatory Bowel Disease (IBD) Therapeutics Market Dynamics
The Inflammatory Bowel Disease (IBD) Therapeutics Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Inflammatory Bowel Disease (IBD) Therapeutics Market Segmentations
Market Breakup by Drug Class
- Overview
- Biologics
- Immunomodulators
- Corticosteroids
- Antibiotics
- 5-Aminosalicylic Acid (5-ASA)
Market Breakup by Route of Administration
- Overview
- Oral
- Injectable
- Topical
Market Breakup by End User
- Overview
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Homecare Settings
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Inflammatory Bowel Disease (IBD) Therapeutics Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- AbbVie
- Johnson & Johnson
- Takeda Pharmaceutical Company
- Bristol-Myers Squibb
- Amgen
- Merck & Co.
- Roche
- Novartis
- Pfizer
- Gilead Sciences
- Eli Lilly and Company
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved